Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Baxter
Dow
Merck

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re: MYLAN N.V. SECURITIES LITIGATION (S.D.N.Y. 2016)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in In Re: MYLAN N.V. SECURITIES LITIGATION
The small molecule drug covered by the patents cited in this case is ⤷  Free Forever Trial .

Details for In Re: MYLAN N.V. SECURITIES LITIGATION (S.D.N.Y. 2016)

Date Filed Document No. Description Snippet Link To Document
2019-04-19 103 Answer to Amended Complaint that U.S. Patent Numbers 7,449,012, 7,794,432, 8,048,035 and 8,870,827 each have a patent expiration…Technologies Inc. is the assignee to U.S. Patents Nos. 7,449,012, 7,794,432, 8,048,035, 8,870,827 and 9,…Technologies, Inc. is the assignee for U.S. Patent Numbers 7,449,012, 7,794,432, 8,048,035 and 8,870,827, and…095,664, filed Apr. 1, 2005, now U.S. Pat. No. 7,449,012, which claims the benefit of U.S. Provisional …information, U.S. Patent Number 4,031,893 was filed on May 14, 1976, that U.S. Patent Number 4,031,893 External link to document
2019-06-17 114 Amended Complaint expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, …submitted information concerning the ’012 patent and ’432 patent for listing in the FDA’s [Orange Book External link to document
2019-07-31 123 Third Amended Complaint expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, …submitted information concerning the ’012 patent and ’432 patent for listing in the FDA’s [Orange Book External link to document
2020-04-27 144 Answer to Amended Complaint that U.S. Patent Numbers 7,449,012; 7,794,432; 8,048,035 and 8,870,827 each have a patent expiration…Technologies Inc. is the assignee to U.S. Patent Nos. 7,449,012; 7,794,432; 8,048,035; 8,870,827; and 9,…Technologies, Inc. is the assignee for U.S. Patent Numbers 7,449,012; 7,794,432; 8,048,035 and 8,870,827, and…095,664, filed Apr. 1, 2005, now U.S. Pat. No. 7,449,012, which claims the benefit of U.S. Provisional …information, U.S. Patent Number 4,031,893 was filed on May 14, 1976, that U.S. Patent Number 4,031,893 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Medtronic
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.